| Id: | acc3668 |
| Group: | 1sens |
| Protein: | Akt |
| Gene Symbol: | Akt1 |
| Protein Id: | P47196 |
| Protein Name: | AKT1_RAT |
| PTM: | phosphorylation |
| Site: | Thr308 |
| Site Sequence: | GIKDGATMKTFCGTPEYLAPE |
| Disease Category: | Endocrine and metabolic diseases |
| Disease: | Obese |
| Disease Subtype: | insulin resistance |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | rosiglitazone |
| Drug Info: | Rosiglitazone is a thiazolidinedione antidiabetic drug that works by improving insulin sensitivity. |
| Effect: | modulate |
| Effect Info: | Rosiglitazone and PPARγ agonists enhance insulin-induced Akt phosphorylation and strengthen insulin signaling. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 12145152 |
| Sentence Index: | 12145152_2 |
| Sentence: | "In this study, we showed that, in Zucker obese (fa/fa) rats, acute (1-day) treatment with both rosiglitazone (a TZD) and a non-TZD PPARgamma agonist (nTZD) reduced plasma free fatty acid and insulin levels and, concomitantly, potentiated insulin-stimulated Akt phosphorylation at threonine 308 (Akt-pT308) in adipose and muscle tissues." |
Sequence & Structure:
MNDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVEQRESPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKRQEEETMDFRSGSPSDNSGAEEMEVALAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPTQRLGGGSEDAKEIMQHRFFANIVWQDVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 308 | D | Obesity | Phosphorylation | 16267124 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
